One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Editorial introductions
Editor(s): Abramson, Steven B.; Yazici, Hasan; Yazici, Yusuf; Attur, Mukundan
doi : 10.1097/BOR.0000000000000857
January 2022 - Volume 34 - Issue 1 - p v-vi
Editorial: Introduction, Vasculitis 2021
Yazici, Hasana; Yazici, Yusufb
doi : 10.1097/BOR.0000000000000856
January 2022 - Volume 34 - Issue 1 - p 1-3
The association of Behçet's syndrome with HLA-B51 as understood in 2021
Takeno, Mitsuhiro
doi : 10.1097/BOR.0000000000000846
January 2022 - Volume 34 - Issue 1 - p 4-9
Animal models of vasculitis
Shochet, Lania,b; Kitching, A. Richarda,b,c
doi : 10.1097/BOR.0000000000000848
January 2022 - Volume 34 - Issue 1 - p 10-17
Vasculitis describes a wide spectrum of rare, inflammatory, multisystem disorders. These heterogenous diseases all have inflammation of blood vessels as a central feature. However, they differ in terms of their genetic and environmental risk factors, disease pathogenesis, clinical presentations and treatment strategies. Many animal models of vasculitis exist, each resembling a different human clinical phenotype. This review provides an overview of recently published findings from experimental animal models of vasculitis.
Takayasu arteritis
Esatoglu, Sinem Nihala; Hatemi, Gulenb
doi : 10.1097/BOR.0000000000000852
January 2022 - Volume 34 - Issue 1 - p 18-24
The purpose of this review is to summarize the recent advances in Takayasu arteritis (TAK), mainly focusing on pathogenesis, imaging modalities, and management.
Updates in cutaneous manifestations of systemic vasculitis
Elbendary, Amiraa; Abdel-Halim, Mona R.E.a; Ragab, Gaafarb
doi : 10.1097/BOR.0000000000000847
January 2022 - Volume 34 - Issue 1 - p 25-32
The main purpose of this review is to present newly reported cutaneous manifestations of systemic vasculitis, updates in investigations to verify systemic involvement in cases with cutaneous vasculitis and new therapeutic guidelines. The spectrum of COVID-19-related vasculitis is also covered.
Patient reported outcomes in systemic vasculitis
Crawshaw, Helenaa; Wells, Matthewb; Austin, Keziahc; Janagan, Shalinid; Robson, Joanna C.d,e
doi : 10.1097/BOR.0000000000000850
January 2022 - Volume 34 - Issue 1 - p 33-38
This review paper evaluates the use of patient reported outcome (PROs) in systemic vasculitis and the increasing incorporation of these measures in the evaluation of clinical outcomes and healthcare provision.
A treat-to-target approach is needed for Behçet's syndrome
Hatemi, Gülena,b
doi : 10.1097/BOR.0000000000000854
January 2022 - Volume 34 - Issue 1 - p 39-45
Treat-to-target (T2T) approach has improved outcomes in chronic diseases. The aim of this review is to discuss the long-term goals and review the evidence for possible targets that would predict the achievement of these goals for developing a T2T strategy for Behçet's syndrome.
Is osteoarthritis a mitochondrial disease? What is the evidence
Fernández-Moreno, Mercedesa; Rego-Pérez, Ignacioa; Blanco, Francisco J.a,b
doi : 10.1097/BOR.0000000000000855
January 2022 - Volume 34 - Issue 1 - p 46-53
To summarize the evidence that suggests that osteoarthritis (OA) is a mitochondrial disease.
Blood and urine biomarkers in osteoarthritis – an update on cartilage associated type II collagen and aggrecan markers
Bay-Jensen, Anne C.a; Mobasheri, Alib,c,d,e,f; Thudium, Christian S.a; Kraus, Virginia B.g; Karsdal, Morten A.a
doi : 10.1097/BOR.0000000000000845
January 2022 - Volume 34 - Issue 1 - p 54-60
Osteoarthritis (OA) is a painful disease for which drug development has proven difficult. One major reason for this is the heterogeneity of the disease and the current lack of operationalized means to distinguish various disease endotypes (molecular subtypes). Biomarkers measured in blood or urine, reflecting joint tissue turnover, have been developed and tested during the last decades. In this narrative review, we provide highlights on biomarkers derived from the two most studied and abundant cartilage proteins – type II collagen and aggrecan.
Ribosome dysfunction in osteoarthritis
van den Akker, Guus G.H.a,?; Caron, Marjolein M.J.a,?; Peffers, Mandy J.c,†; Welting, Tim J.M.a,b,†
doi : 10.1097/BOR.0000000000000858
January 2022 - Volume 34 - Issue 1 - p 61-67
Translation of genetic information encoded within mRNA molecules by ribosomes into proteins is a key part of the central dogma of molecular biology. Despite the central position of the ribosome in the translation of proteins, and considering the major proteomic changes that occur in the joint during osteoarthritis development and progression, the ribosome has received very limited attention as driver of osteoarthritis pathogenesis.
Did COVID-19 impact osteoarthritis – clinical perspective?
Alhassan, Eamana; Siaton, Bernadette C.b; Hochberg, Marc C.b,c
doi : 10.1097/BOR.0000000000000851
January 2022 - Volume 34 - Issue 1 - p 68-72
To assess the impact of the coronavirus disease 2019 (COVID-19) pandemic on patients with osteoarthritis (OA).
Bone in osteoarthritis: imaging and interventions
Khokhar, Kiran; Conaghan, Philip G.
doi : 10.1097/BOR.0000000000000849
January 2022 - Volume 34 - Issue 1 - p 73-78
To review the recent literature on bone in osteoarthritis (OA), with a focus on imaging and intervention studies
Insights into the molecular landscape of osteoarthritis in human tissues
Katsoula, Georgiaa,c; Kreitmaier, Petera,c; Zeggini, Eleftheriab,c
doi : 10.1097/BOR.0000000000000853
January 2022 - Volume 34 - Issue 1 - p 79-90
To provide an overview of recent developments in the field of osteoarthritis research with a focus on insights gleaned from the application of different -omic technologies.
Metabolic perturbations in systemic sclerosis
O’Reilly, Steven
doi : 10.1097/BOR.0000000000000824
January 2022 - Volume 34 - Issue 1 - p 91-94
The aim of this review is to evaluate the recent evidence of the role of metabolism in systemic sclerosis (SSc), highlighting specific aberrations and to appraise the feasibility of targeting these therapeutically.
